



9803/p00751 20 AUG 2004



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 20 MAR 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

P. Mahoney

Dated

12 March 2003

Patents Form 1/77

Patents Act 1977
(Rule 16)




1177

25FEB02 E698366-3 D00192
F01/7700 0.00-0204232.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference	N83994 PEJ/SER		
2. Patent at (The Patent)	0204232.3		22 FEB 2002
3. Full name, address and postcode of the or each applicant (underline all surnames)	Isis Innovation Limited Ewert House, Ewert Place Summertown Oxford OX2 7SG		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of its incorporation	GB	3998564002	
4. Title of the invention	ASSAY		
5. Name of your agent (if you have one)	J.A. KEMP & CO.		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	14 South Square Gray's Inn London WC1R 5JJ		
Patents ADP number (if you know it)	26001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	14	/
Claim(s)	2	/
Abstract	1	/
Drawing(s)	12 + 12	/

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

1 ✓

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

J.A. Kemp + Co

Date 22 February 2002

J.A. KEMP & CO.

12. Name and daytime telephone number of person to contact in the United Kingdom

SARAH ROQUES
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

ASSAY

Field of the Invention

This invention relates to an assay for determining the amount of NADPH (nicotinamide adenine dinucleotide phosphate) or NADH (nicotinamide adenine dinucleotide) present in a sample.

Background of the Invention

NADH and NADPH are physiological substances which occur in all living cells including human cells. Both are byproducts of a large number of redox enzymes and in particular dehydrogenases. Many dehydrogenases employ NAD^+ or NADP^+ as a cofactor. As the substrate of the dehydrogenase is oxidised, NAD^+ or NADP^+ is simultaneously reduced to NADH or NADPH. This reduction involves the transfer of two electrons plus a proton (or hydride transfer) to the NAD^+ or NADP^+ to generate the NADH or NADPH. In the case of some dehydrogenases, such as glutamate dehydrogenase, the reaction can be driven in the reverse direction.

A large range of dehydrogenases exist and carry out a number of biologically important functions. Substrates for the dehydrogenases include biological important compounds such as amino acids, lactate, cholesterol and glycerol. It is important to be able to monitor the amount of these compounds and assays exist which employ dehydrogenases to measure the amount of such metabolites in biological samples.

The assays typically measure the amount of NADH or NADPH produced as the dehydrogenase oxidises the substrate and hence allow the quantification of the substrate. These assays typically employ spectrophotometric methods to detect the amount of NADH or NADPH. However, such spectrophotometric assays are cumbersome and require skilled operators to carry them out. Additionally, problems or costs may be involved where the sample contains high amounts of a protein which absorbs at the wavelength being measured or structures such as blood cells which also interfere with the absorbance. This may mean extra processing steps have to be carried out.

Electrochemical methods have been attempted to try and measure the amount of NADH or NADPH. However, the only methods developed so far typically use organic dyes such as Methylene blue and methyl-viologen or diaphorase as mediators and these are

unstable and are frequently toxic. In addition, the electrochemical methods typically use electron acceptors that can only accept a single electron at a time from NADH or NADPH or which are too slow meaning that too small a current is produced or the current produced is not proportional to the amount of substrate present and hence quantitative results cannot be obtained.

Summary of the Invention

The present invention is based on the finding that a class of redox proteins known as reductases can simultaneously accept two electrons from NADH or NADPH and rapidly transfer them to a small, redox active molecule. The re-oxidation of the redox active molecule can then be detected, typically by using electrochemical methods. The fast rate of electron transfer reduction of the redox active small molecule complex by the reductase means that an effective, catalytic current can be generated which is limited by, and therefore linear to, the substrate concentration. This means results can be obtained which are truly quantitative. The method also allows measurement over time. Therefore NADH or NADPH can be effectively quantified electrochemically without the need for toxic, unstable organic dyes. The assay is also far simpler to carry out than those in the art, meaning less experience is required to carry it out and reducing its expense.

Accordingly, the present invention provides a method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample comprising;

- adding a reductase and a redox active agent to said sample; and
- measuring the quantity of reduced redox active agent produced by the reductase.

The invention further provides an electrochemical cell comprising:

- sample holding means;
- a source of reductase;
- a redox active agent; and
- means for detecting and/or quantifying any current generated.

The invention also provides a kit comprising:


- a reductase;
- a redox active agent; and
- a means for detecting the reduction of the redox active agent.

Detailed description of the Invention

Throughout the present specification and the accompanying claims the words "comprise" and "include" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

General scheme for Assay

The general scheme for the assay system of the invention is as follows:



Although most commonly the assay scheme is as indicated above, the system can effectively be run in reverse, with electrons and a proton being transferred from the reductase to NAD⁺ or NADP⁺ to generate NADH or NADPH respectively.

The purpose of the assay may be to detect and/or quantify the amount of the:

- redox enzyme;
- substrate; or
- NADH, NADPH, NAD⁺, or NADP⁺ or an analog of any of these present in the biological sample.

The assay system may also involve additional steps. For example, additional stages may be involved after the reductase or before the redox enzyme indicated above. Such additional steps may also involve the transfer of electrons and will typically be enzyme catalysed. Where there are additional steps before the redox enzyme which converts NAD⁺ or NADP⁺ to NADH or NADPH or *vice versa* the purpose of the assay may be to measure the amount of an enzyme or compound upstream of the redox enzyme.

In one embodiment, the upstream events involve the release of a bound substance

which can then be detected. Typically, the bound substance may be released enzymatically. For example the bound substance may be cholesterol and the enzyme catalysing its release may be a lipase. Other substances or cofactors, such as a detergent, may also be present. Once released the substance, such as cholesterol, may then be a
5 substrate for the redox enzyme. In such assays the purpose may be to detect the presence or absence of, or to quantify the amount of, either the bound substance or the enzyme catalysing its release. Preferably the assay will be used to detect and/or quantify the bound substance.

Analyte or enzyme to be measured

10 The redox enzyme responsible for the initial step in the assay may be any of a number of possible enzymes and the purpose of the assay may be to measure the amount of that enzyme or its substrate. The enzyme will be matched with the substrate so that appropriate pairings are chosen i.e. that the enzyme can oxidise or reduce the substrate using the nicotinamide adenine dinucleotide as a cofactor, typically the enzyme will
15 oxidise the substrate and reduce NAD^+ , or NADP^+ . The enzyme may be a recombinant enzyme or one from a natural source.

Examples of possible enzymes which may be used or quantified include glycerol dehydrogenase, glucose dehydrogenase, glutamate dehydrogenase, cholesterol dehydrogenase, ethylene glycol dehydrogenase, lactate dehydrogenase, alcohol
20 dehydrogenase, α -hydroxybutyrate dehydrogenase, isocitric dehydrogenase, sorbitol dehydrogenase, aspartate aminotransferase, and alanine amino-transferase. In a preferred embodiment of the invention the redox enzyme is a dehydrogenase and more preferably is glycerol dehydrogenase, glucose dehydrogenase glutamate dehydrogenase, ethylene glycol dehydrogenase, cholesterol dehydrogenase, lactate dehydrogenase, or alcohol
25 dehydrogenase.

Any of a large number of compounds may be used as the substrate. The substrate may be a biologically important molecule such as urea, uric acid, ammonia, lactic acid, triglyceride, LDL, salicylate, glucose, pyruvic acid, carbon dioxide, adenosine 5'-triphosphate, or 2,3-diphosphoglycerate. Alternatively, the substrate may be a drug or a
30 metabolite of a drug.

In some embodiments of the invention, the actual purpose of carrying out the assay

may be to quantify NADH, NADPH, NAD^+ , or NADP^+ itself. For example, this may be to study biological systems in which these compounds are involved. Alternatively, NADH and NADPH have been used to treat a number of conditions including such as atherosclerosis, AIDS, cancer, chronic fatigue syndrome, Parkinson's and Alzheimer's and the assay of the invention may be used to measure NADH or NADPH in biological samples from subjects to whom these compounds have been administered.

The amount of substrate, enzyme, NADH, NADPH, NAD^+ , or NADP^+ employed in the assay will typically depend on what exactly is being measured and the system being used to measure the transfer of electrons through the reductase. One of the substrate, enzyme, NADH, NADPH, NAD^+ , or NADP^+ will typically be present in an unknown amount as it is the substance being quantified. Typically, where that compound is not the one being quantified, the amount of:

- redox enzyme present will be from 1 to $100\mu\text{M}$, preferably from 5 to $75\mu\text{M}$, and even more preferably from 5 to $50\mu\text{M}$;
- reductase present will be from 0.001 to $100\mu\text{M}$, preferably from 0.1 to $50\mu\text{M}$, and even more preferably from 1 to $10\mu\text{M}$;
- NAD^+ , or NADP^+ present will be from 0.1 to 100mM , preferably from 0.1 to 75mM , and even more preferably from 0.1 to 50mM ; and/or
- redox active agent will be from 1 to 100mM , preferably from 1 to 25mM , and even more preferably from 1 to 10mM .

Instead of using NADH, NADPH, NAD^+ , or NADP^+ , the assay may employ an analog of one of these compounds. Such analogs will typically be artificial or synthetic analogs chosen for particular characteristics such as their increased stability or the way in which they interact with a particular redox enzyme.

25 *Reductases*

The use of a reductase in the assay of the invention allows the rapid transfer of electrons either from the NADH or NADPH to the redox active agent or *vice versa*. The reductase typically receives two electrons from the NADH or NADPH and it is this acceptance of two electrons simultaneously followed by their rapid transfer individually to the redox active agent which allows a significant current to be generated, the size of which is directly proportional to the amount of substrate present and hence allowing meaningful,

accurate results to be obtained.

The reductase employed may be any reductase capable of transferring the electrons rapidly enough to allow a detectable current to be generated. Preferred reductases include cytochrome P450 reductases. In particular, preferred reductases include the putidaredoxin
5 reductase of the cytochrome P450_{cam} enzyme system from *Pseudomonas putida*, the flavin (FAD/FMN) domain of the P450_{BM-3} enzyme from *Bacillus megaterium*, spinach ferredoxin reductase, rubredoxin reductase, adrenodoxin reductase, nitrate reductase, cytochrome *b₅* reductase, corn nitrate reductase, terpredoxin reductase and yeast, rat, rabbit
10 and human NADPH cytochrome P450 reductases. Where a nitrate reductase is employed preferably corn nitrate reductase is used. Particularly preferred reductases for use in the invention are putidaredoxin reductase and flavin domain of P450_{BM-3} as these are capable of particularly rapid electron transfer and hence allow optimal results to be obtained.

The reductase may be a recombinant protein or a naturally occurring protein which has been purified or isolated. The reductase may have been mutated to improve its
15 performance such as to optimise the speed at which it carries out the electron transfer or its substrate specificity. The amount of reductase employed will depend on the exact nature of what is measured and the particular details of the assay but typically, the reductase will be present at a concentration of from 0.001 to 100 μ M, preferably from 0.01 to 50 μ M, more preferably from 0.1 to 25 μ M, and even more preferably from 1 to 10 μ M.

20 For putidaredoxin reductase, typically the amount of enzyme employed will be from 100 to 10,000 ca, preferably from 1000 to 5000 ca, more preferably from 2000 to 4000 ca and even more preferably will be 3000 ca. The ca is the unit of activity of putidaredoxin reductase in mediating the oxidation of NADH by ferricyanide and is defined as 1 μ mole of NADH oxidised per mg reductase per minute.


25 The general nature of reduction of small molecules by the reductase means the redox potential at which the small molecule mediator is detected can be tuned by standard methods of coordination chemistry so as to avoid interference from redox active molecules found in naturally occurring biological fluids.

Redox active agent

30 A redox active agent is employed to accept the electrons from the reductase. Typically, the redox active agent will accept the electrons one at a time. The redox agent

may be a redox active molecule or inorganic complex. The agent may be a naturally occurring electron acceptor such as a protein or may be a synthetic molecule. The agent will typically have at least two oxidation states to allow it to accept electrons from the reductase.

- 5 Preferably, the redox agent is an inorganic complex. The agent may comprise a metallic ion and will preferably will have at least two valencies. In particular, the agent may comprise a transition metal ion and preferred transition metal ions include those of cobalt, copper, iron, chromium, manganese, nickel, or ruthenium. The redox agent may be charged, for example it may be cationic or alternatively anionic. An example of a suitable cationic agent is a ruthenium complex such as $\text{Ru}(\text{NH}_3)_6^{3+}$, an example of a suitable anionic agent is a ferricyanide complex such as $\text{Fe}(\text{CN})_6^{3-}$. The reaction scheme for each would respectively be:
- 10



- The agent may be hydrophobic, for example a ferrocenium complex may be used, or may be hydrophilic. Example of complexes which may be used include $\text{Cu}(\text{EDTA})^{2-}$, $\text{Fe}(\text{CN})_6^{3-}$, $\text{Fe}(\text{CN})_5(\text{O}_2\text{CR})^{3-}$, $\text{Fe}(\text{CN})_4(\text{oxalate})^{3-}$, $\text{Ru}(\text{NH}_3)_6^{3+}$ and chelating amine ligand derivatives thereof (such as ethylenediamine), $\text{Ru}(\text{NH}_3)_5(\text{py})^{3+}$, ferrocenium and derivatives
- 15

thereof with one, or more of groups such as $-NH_2$, $-NHR$, $-NHC(O)R$, and $-CO_2H$ substituted into one or both of the two cyclopentadienyl rings. Preferably the inorganic complex is $Fe(CN)_6^{3-}$, $Ru(NH_3)_6^{3+}$, or ferrocenium monocarboxylic acid (FMCA).

5 The agent has to interact with the reductase and hence particular combinations of agent and reductase may provide optimal results in terms of the rate of electron transfer or the charge produced or other desirable characteristics. For example, the reductase may have particular amino acids near its active site which mean that a hydrophobic redox agent is best or alternatively the region may contain positive or negatively charged residues or polar groups and hence an anionic or cationic redox agent may be more suitable. The
10 particular pair of enzyme and redox agent will be chosen to complement each other and hence to provide optimal results. Preferred pairings include $Fe(CN)_6^{3-}$ or $Ru(NH_3)_6^{3+}$ with putidaredoxin reductase or the flavin domain of $P450_{BM-3}$ and either $Fe(CN)_6^{3-}$ or $Ru(NH_3)_6^{3+}$ with spinach ferredoxin reductase. The choice of redox agent may also be influenced by the means used to detect the charge produced such as the electrode used.

15 The concentration of redox reagent used may vary depending on what is being measured and the other components in the assay, but typically may be in the range of 0.01 to 500mM, preferably from 0.1 to 100 mM, more preferably from 1 to 50 mM, and even more preferably from 5 to 25mM.

Detection methods

20 The transfer of electrons to the redox agent to the redox agent is detected. This is preferably done by electrochemical means, although if desired NADH and NADPH concentrations can be measured at a wavelength of 340nm or the $Fe(CN)_6^{3-}$ concentration at 420nm.

25 Typically, the redox agent will transfer electrons to an electrode generating a current. The current generated will typically be proportional to the amount of substrate present in the sample and hence the amount of the substrate can be determined.

A typical sensor system based on electrochemical detection which may be used in the invention will comprise a working electrode, which may be constructed from carbon paste, platinum, gold or some such suitable conducting material, a reference electrode
30 which is typically the $AgCl/Ag$ electrode, and optionally a counter electrode. All electrodes may be fabricated by techniques such as screen printing which are well known

to those familiar with the art. A buffered solution of the dehydrogenase enzyme for converting the target analyte substrate to its product(s), NAD^+ or NADP^+ , a NADH or NADPH reductase, and the redox agent such as ferricyanide or $\text{Ru}(\text{NH}_3)_6^{3+}$, can be deposited onto the electrode system and dried.

5 The whole or part of the sensor system may be covered by a membrane or a number of membranes or filters for example, to separate red cells from a blood sample or to ensure that undesired substances or cells do not enter the sensor.

 When a liquid sample such as blood is applied, the liquid typically enters the sensor compartment and redissolves the mixture of enzymes and redox agent. The target analyte
10 is then oxidised, producing NADH or NADPH which rapidly reduces the reductase. The reductase in turn rapidly reduces the redox agent such as $\text{Ru}(\text{NH}_3)_6^{3+}$ to a reduced form, in this case $\text{Ru}(\text{NH}_3)_6^{2+}$, which is then oxidised by the working electrode set at the appropriate potential. The current produced will be proportional to the concentration of the target analyte.

15 In another embodiment of the invention the working electrode may be located away from the dehydrogenase/ NAD^+ /reductase/redox agent mixture to minimise fouling of the working electrode and thus improve sensor performance.

 By using a dehydrogenase with the appropriate substrate specifically and altering the reaction conditions, for example by including suitable chemical and biological
20 components such as lipids, detergents, surfactants or other proteins, a rapid sensor may be constructed. Additionally another enzyme system can be used to convert a target analyte into a substance which is oxidised by the dehydrogenase and then detected by the present electrochemical method. For example a sensor to detect and or quantify triglycerides may be constructed where triglycerides are cleaved to glycerol and fatty acids by a suitable
25 lipase and the glycerol may then be detected by glycerol dehydrogenase coupled to the reductase/redox agent system of the invention.

Samples

 The assay of the invention may be used to monitor the presence of a particular analyte or enzyme in a wide array of samples. Typically, the sample analysed will be a
30 liquid and will usually be an aqueous fluid. In particular, the sample may be a bodily fluid such as urine, serum, blood or amniotic fluid, cerebrospinal fluid (CSF) or alternatively

may be a fluid such as milk, wine or juice or have been prepared from one of these. The sample may be culture medium from prokaryotic or eukaryotic cells and in particular from mammalian cells. The sample may be a foodstuff or drink or may be the product of an industrial process and the assay used to monitor the product of a compound or the
5 incidence of byproducts or toxic compounds.

Control samples may also be analysed. These may lack one or more of the substrate, redox enzyme, reductase, redox agent, NADH, NADPH, NAD⁺, or NADP⁺. The controls may be obtained from healthy individuals in order to compare them to those of a patient. Reference samples may be used which contain a known amount of the substrate or
10 enzyme to be measured and hence allow calibration of the apparatus and/or standard curves to be drawn up to be compared against the results for the unknown samples. The sample may be serially diluted and several dilutions analysed as the concentration of the substrate or enzyme to be measured might be too high to be effectively measured in undiluted form.

The method of the invention may be used to diagnose or assess the progression of various diseases or to determine the susceptibility of an individual to such diseases.
15 Typically, the method will be used to detect the presence or absence of, or to quantify the amount of a compound or enzyme associated with a disease state. For example, the method may be used to detect or quantify the amount of glucose in urine or blood from a diabetic or alternatively to measure the level of cholesterol or particular enzymes in a
20 patient suffering from heart disease. The method may also be used to measure a compound or enzyme to determine when a drug or therapy needs to be administered to a patient or to measure how much of a drug remains or reached its target once administered. The method may also be used to detect and quantify drugs of abuse in samples from individuals.

The methods of the invention may be used to monitor lipid levels such as
25 cholesterol or triglyceride levels and in particular may be used to quantify the levels of lipids in the blood or plasma. This may allow detection of individuals at risk of conditions associated with abnormal lipid levels such as those associated with elevated levels of a lipid or lipid deficiency. It may also allow monitoring of the progress of treatment of such a condition to assess whether lipid levels have returned to normal. Conditions include
30 atherosclerosis, stroke, cardiovascular disease and heart attack as well as lipid deficiencies resulting from inadequate diet or metabolic defects.

The methods of the invention may also be used to monitor other metabolic defects

such as those involved, for example, in amino acid metabolism. Such conditions include phenylketonuria (PKU) which may be monitored or detected by using phenyl alanine dehydrogenase as the redox enzyme in the system of the invention.

Kits

5 The invention also provides kits for carrying out the methods of the invention. Typically, the kit will comprise:

- a reductase;
- a redox active agent; and
- a means for detecting the reduction of the redox active agent.

10 The kit may also comprise a redox enzyme, preferably a dehydrogenase, and/or the substrate for the redox enzyme. The redox enzyme, the substrate, reductase and redox active agent may be any of those discussed above.

 The means for detecting the reduction of the redox agent may be an electrochemical means, such as an electrochemical cell or its constituent parts, or alternatively, but less
15 preferably, may be spectrophotometric means.

 The kit may include means for detecting and quantify current and optionally a computer system for analysing and displaying the results. The kit may also include various packing and suitable instructions detailing how to use the kit and how it should be stored.

EXAMPLES

20 The following Examples further illustrate the present invention.

Example 1 - spectrophotometric analysis for putidaredoxin reductase

Putidaredoxin reductase is specific to NADH. The oxidation of NADH by $\text{Fe}(\text{CN})_6^{3-}$ catalysed by putidaredoxin reductase was demonstrated by a spectrophotometric assay.

25 1.5 ml of an incubation mixture containing 50mM phosphate buffer, pH 7.4, 0.1nM putidaredoxin reductase, and 1 mM $\text{K}_3\text{Fe}(\text{CN})_6$ was added to cuvettes. A spectrophotometer was used to measure the absorbance at 340nm and set to zero using a cuvette containing the incubation mixture alone.

NADH was then added to some of the cuvettes containing the incubation mixture as

a 30mM stock in 50mM phosphate buffer, pH 7.4 to a final concentration of 300 μ M (A_{340nm} ca, 1.8) and absorbance at 340nm monitored. As shown by Figure 1a, the absorbance due to NADH decreased steadily with time as it was oxidised to NAD⁺ by ferricyanide acting as an oxidising agent in a reaction mediated by putidaredoxin reductase which catalysed the transfer of electrons from one to the other. If either the reductase or ferricyanide was omitted no change in absorbance was seen (Figure 1b). The reaction can also be monitored at the ferrocyanide absorption at 420 nm.

The Ru(NH₃)₆³⁺ reduction assay was carried out under identical conditions except that the putidaredoxin reductase concentration was 1 μ M and the Ru(NH₃)₆³⁺ concentration was 2mM. NADH was added to a final concentration of ca. 300 μ M (A_{340nm} = 1.8) and the NADH absorption at 340 nm was monitored. As shown in Figure 1c the NADH was oxidised in less than 2 minutes. When putidaredoxin reductase (PdR) was absent there was no detectable oxidation of NADH (Figure 1d).

Example 2 - spectrophotometric analysis for the P450_{BM-3} flavin domain

The flavin domain of P450_{BM-3} is specific for NADPH. The oxidation of NADPH by both Fe(CN)₆³⁻ and Ru(NH₃)₆³⁺ catalysed by the flavin domain of P450_{BM-3} was demonstrated by spectrophotometric assays.

1.5 ml of an incubation mixture containing 50 mM phosphate buffer, pH 7.4, 50nM of the flavin domain of P450_{BM-3}, and either 1 mM K₃Fe(CN)₆ or 2 mM Ru(NH₃)₆³⁺ was added to cuvettes. A spectrophotometer was used to measure the absorbance changes at the relevant wavelength.

For the ferricyanide reduction assay, the reaction was monitored at the 420nm absorptions of ferricyanide. NADPH was added to the sample cuvette as a 30 mM stock in 50 mM phosphate, pH 7.4 to a final concentration of ca. 500 μ M (A_{340nm} = 3.0) and the absorbance at 420 nm monitored. As shown in Figure 2, all the ferricyanide was reduced to the ferrocyanide in less than 80 seconds.

For the Ru(NH₃)₆³⁺ reduction assay, the reaction was monitored at the NADPH absorptions at 340 nm. NADPH was added to a final concentration of ca.300 μ M (A_{340nm} = 1.8). As shown in Figure 3, all the NADPH was consumed in less than 90 seconds.

Example 3 - spectrophotometric analysis for spinach ferredoxin reductase

Spinach ferredoxin reductase is specific for NADPH. The oxidation of NADPH by both $\text{Fe}(\text{CN})_6^{3-}$ and $\text{Ru}(\text{NH}_3)_6^{3+}$ catalysed by spinach ferredoxin reductase was demonstrated by spectrophotometric assays.

1.5ml of an incubation mixture containing 50mM phosphate buffer, pH 7.4, 0.05 units of spinach ferredoxin reductase, and either 1 mM $\text{K}_3\text{Fe}(\text{CN})_6$ or 2 mM $\text{Ru}(\text{NH}_3)_6^{3+}$ was added to cuvettes. A spectrophotometer was used to measure the absorbance changes at the relevant wavelength.

For the ferricyanide reduction assay, the reaction was monitored at the 420nm absorptions of ferricyanide reduction assay, the reaction was monitored at the 420nm absorptions of ferricyanide. NADPH was added to the sample cuvette as a 30mM stock in 50mM phosphate, pH 7.4 to a final concentration of ca. 500 μM ($A_{340\text{nm}} = 3.0$) and the absorbance at 420nm monitored. As shown in Figure 4a, all the ferricyanide was reduced to the ferrocyanide in approximately 60 seconds. NADPH oxidation was much slower when either the reductase or ferricyanide was absent, see Figure 4b, 4c.

For the $\text{Ru}(\text{NH}_3)_6^{3+}$ reduction assay, the reaction was monitored at the NADPH absorptions at 340nm. NADPH was added to a final concentration of ca. 400 μM ($A_{340\text{nm}} = 2.5$). As shown in Figure 5a, all the NADPH was consumed in less than 90 seconds. NADPH oxidation was much slower when either the reductase or $\text{Ru}(\text{NH}_3)_6^{3+}$ was absent, see Figure 5b, 5c.

Example 4 - electrochemical analysis

A sensor system based on electrochemical detection may be constructed using a working electrode, constructed from carbon paste, platinum, gold or some such suitable conducting material, a reference electrode which is a AgCl/Ag electrode, and optionally a counter electrode. The electrodes may be prepared using screen printing.

A buffered solution of the dehydrogenase enzyme for converting the target analyte substrate to its product(s), NAD^+ or NADP^+ , a NADH or NADPH reductase, and ferricyanide or $\text{Ru}(\text{NH}_3)_6^{3+}$ as a redox agent, can be deposited onto the electrode system and dried.

A liquid sample is applied to the system, the liquid enters the sensor compartment and redissolves the mixture of enzymes and redox agent. The target analyte is then oxidised, producing NADH or NADPH which rapidly reduces the reductase. The

reductase may be putidaredoxin reductase where NADH is used or the flavin domain of P450_{BM-3} or the spinach ferredoxin reductase where NADPH is employed. The reductase in turn rapidly reduces the redox agent such as $\text{Ru}(\text{NH}_3)_6^{3+}$ or $\text{Fe}(\text{CN})_6^{3-}$ to a reduced form, in other words to $\text{Ru}(\text{NH}_3)_6^{2+}$ or $\text{Fe}(\text{CN})_6^{4-}$ respectively. The $\text{Ru}(\text{NH}_3)_6^{2+}$ or $\text{Fe}(\text{CN})_6^{4-}$ is then
5 oxidised by the working electrode set at the appropriate potential. The current produced is proportional to the concentration of the target analyte. Various solutions containing a known amount of the analyte may be employed to calibrate the system and/or to produce standard curves allowing the concentration of the analyte to be determined in the sample being tested.

CLAIMS

1. A method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample comprising;

- adding a reductase and a redox active agent to said sample; and
- 5 - measuring the quantity of reduced redox active agent produced by the reductase.

2. A method according to claim 1, wherein the NADH or NADPH are produced by the reduction of NAD^+ or NADP^+ by a redox enzyme which concomitantly oxidises a substrate.

10 3. A method according to claim 2, wherein the amount of NADH or NADPH formed is proportional to the amount of the redox enzyme present or the amount of its substrate and hence allows the detection, or quantification of the enzyme or substrate in the sample.

15 4. A method according to claim 2 or 3, wherein the redox enzyme is a dehydrogenase.

1 5. A method according to any one of the preceding claims wherein the redox active agent is $\text{Fe}(\text{CN})_6^{3-}$, $\text{Ru}(\text{NH}_3)_6^{3+}$, or ferrocenium monocarboxylic acid (FMCA).

20 6. A method according to any one of the preceding claims wherein the reductase is selected from putidaredoxin reductase of the cytochrome P450_{cam} enzyme system from *Pseudomonas putida*, the flavin (FAD/FMN) domain of the $\text{P450}_{\text{BM-3}}$ enzyme from *Bacillus megaterium*, spinach ferredoxin reductase, rubredoxin reductase, adrenodoxin reductase, nitrate reductase, cytochrome b_5 reductase, corn nitrate reductase, terpredoxin reductase and yeast, rat, rabbit and human NADPH cytochrome P450 reductase or a functional derivative of any thereof.

25 7. A method according to any one of the preceding claims wherein the reductase is specific for NADH.

8. A method according to claim 7 wherein the reductase is a putidaredoxin reductase.

30 9. A method according to any one of claims 1 to 6 wherein the reductase is specific for NADPH.

10. A method according to claim 9 wherein the reductase is the flavin domain

of P450_{BM-3} or is spinach ferredoxin reductase.

11. A method according to anyone of the preceding claims wherein the presence, absence or amount of the reduced redox agent formed is measured by electrochemical means.

5 12. A method according to any one of the preceding claims which allows a monitoring of the amount of the substrate, enzyme, NADH or NADPH over time.

13. An electrochemical cell comprising:

- sample holding means;
- a source of reductase;
- 10 - a redox active agent; and
- means for detecting and/or quantifying any current generated.

14. An electrochemical cell according to claim 13, which can be used to carry out a method as defined in any one of claims 1 to 12.

15. A kit comprising:

- 15 - a reductase;
- a redox active agent; and
- a means for detecting the reduction of the redox active agent.

16. A kit according to claim 15, which can be used to carry out a method as defined in any one of claims 1 to 12.

20

ABSTRACT

ASSAY

A method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample is provided, wherein the method
5 comprises

- adding a reductase and a redox active agent to said sample; and
- measuring the quantity of reduced redox active agent produced by the reductase.

The method may be used to quantify the amount of a redox enzyme capable of oxidising a
10 substrate and concomitantly reducing NAD⁺ or NADP⁺ or may be used to quantify the amount of the substrate of that enzymes.




FIGURE 1a




FIGURE 1b

3/12




FIGURE 1c

4/12





FIGURE 1d



6/12




FIGURE 3

7/12




FIGURE 4(a)

8/12




FIGURE 4(b)




FIGURE 4(c)




FIGURE 5(a)

11/12




FIGURE 5(b)

12/12




FIGURE 5(c)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.